Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin).
The relationships between resistance to adriamycin, vincristine, colchicine and etopside, expression of P-glycoprotein and CP22 (sorcin), and resistance modification by verapamil and cyclosporin A have been studied in a panel of multidrug-resistant (MDR) mouse tumour cell lines. Whereas there was a generally good correlation between the degree of resistance and the amount of P-glycoprotein, no relationship between resistance and CP22 expression was seen. At 3.3 microM verapamil, the sensitisation of the MDR cell lines was no greater than that of the parent line. At 6.6 microM verapamil, however, sensitisation of the MDR lines generally exceeded that of the parent line, although the line CR 2.0, expressing very high levels of P-glycoprotein was an exception. Little sensitisation to etoposide was seen in any of the lines. When cyclosporin A was used as the sensitiser at either 2.1 or 4.2 microM, there was a greater effect in lines expressing moderate to high levels of P-glycoprotein than in the parent line, although this tendency was less for adriamycin than for the other cytotoxics. Sensitisation to etoposide was much greater with cyclosporin A than with verapamil. At low levels (less than 1 microM) of CsA, however, sensitisation to colchicine was greater in the parent line than in cell line CR 2.0. These studies indicate that chemosensitisation by verapamil and cyclosporin A is extremely complex, depending upon sensitiser dose, the particular cytotoxic and the cell line. At low doses of the sensitisers, the sensitisation may be greater in lines expressing low levels of P-glycoprotein than in lines showing high levels.
Twentyman
P R
PR
MRC Clinical Oncology, MRC Centre, Cambridge, UK.
Reeve
J G
JG
Koch
G
G
Wright
K A
KA
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000818:Animals; D015153:Blotting, Western; D002135:Calcium-Binding Proteins / Q000096:biosynthesis*; D002296:Carcinosarcoma / Q000188:drug therapy* / Q000378:metabolism; D002460:Cell Line; D003078:Colchicine / Q000494:pharmacology; D003524:Cyclosporins / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000494:pharmacology; D004351:Drug Resistance / Q000502:physiology*; D005047:Etoposide / Q000494:pharmacology; D015870:Gene Expression; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy* / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000096:biosynthesis*; D051379:Mice; D009363:Neoplasm Proteins / Q000096:biosynthesis*; D014700:Verapamil / Q000494:pharmacology*; D014750:Vincristine / Q000494:pharmacology
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D002135:Calcium-Binding Proteins; D003524:Cyclosporins; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; C503114:Sri protein, mouse; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D014700:Verapamil; D003078:Colchicine